Clinical Trials & Research Studies in United Kingdom(Updated 8/25)

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

NCT05734196

Recruiting

The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.

Gender:

ALL

Ages:

1 year and below

Trial Updated:

02/06/2025

Locations: Rady Children's Hospital, San Diego, California +6 locations

Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum

Register for Updates

Learn More ›

Investigating the Impacts of Early Life Experience on the Brain & Behaviour

NCT06823492

Recruiting

The aim of this study is to learn more about how early life experience influences the brain, behaviour, and the immune system later in life. This will help improve understanding of why certain early life experiences (e.g., adoption, stress and parental separation) can cause difficulties for some people when they are adults. The long-term goal of this research is to develop tools that could identify young people who are vulnerable to developing future problems, this will ensure people get the hel... Read More

Gender:

ALL

Ages:

Between 18 years and 25 years

Trial Updated:

02/06/2025

Locations: Faculty of Biology Medicine & Health, University of Manchester, Manchester, Not set

Conditions: Mental Health, Neurodevelopment, ADHD, Autism, Depression - Major Depressive Disorder, Anxiety Disorder (Panic Disorder or GAD)

Register for Updates

Learn More ›

Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery

NCT06246136

Recruiting

The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or competitor device in reducing IOP at 12 months postoperatively.

Gender:

ALL

Ages:

40 years and above

Trial Updated:

02/06/2025

Locations: ELIOS Clinical Site, Leuven, Not set +12 locations

Conditions: Open Angle Glaucoma

Register for Updates

Learn More ›

Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease

NCT06347536

Recruiting

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease affecting approximately 10% of the adult population globally. COPD is recognised to be an important area of focus, as part of one of the healthcare challenges defined by the Office of Life Sciences. Patients with COPD often experience exacerbations which are triggered episodes leading to disease worsening. Exacerbations are associated with increased morbidity and a risk of mortality. Severe exacerbations, where patients are... Read More

Gender:

ALL

Ages:

40 years and above

Trial Updated:

02/06/2025

Locations: Barnsley Hospital NHS Foundation Trust, Barnsley, Not set +33 locations

Barnsley Hospital NHS Foundation Trust, Barnsley, Not set

University Hospitals Birminham NHS Foundation Trust, Birmingham, Not set

Blackpool Teaching Hospitals, Blackpool, Not set

Bradford Teaching Hospitals NHS Foundation Trust, Bradford, Not set

University Hospitals Sussex NHS Foundation Trust, Brighton, Not set

North Bristol University Trust, Bristol, Not set

County Durham and Darlington NHS Foundation Trust, Durham, Not set

Gateshead NHS Foundation Trust, Gateshead, Not set

East Suffolk and North Essex Foundation Trust, Ipswich, Not set

University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, Not set

University Hospitals of Leicester NHS Trust, Leicester, Not set

Cardiff and Vale University Health Board, Llandough, Not set

Guy's and St Thomas' NHS Foundation Trust, London, Not set

Imperial College Healthcare NHS Trust, London, Not set

King's College Hospital, London, Not set

London North West University Healthcare NHS Trust, London, Not set

Royal Free London NHS Foundation Trust, London, Not set

Maidstone and Tunbridge Wells NHS Trust, Maidstone, Not set

South Tees NHS Foundation Trust, Middlesbrough, Not set

Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, Not set

Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Not set

Nottingham University Hospitals Trust, Nottingham, Not set

Oxford University Hospitals NHS Foundation Trust, Oxford, Not set

Rotherham NHS Foundation Trust, Rotherham, Not set

University Hospital Southampton NHS Foundation Trust, Shirley, Not set

Frimley Health NHS Foundation Trust, Slough, Not set

South Tyneside and Sunderland NHS Trust, South Shields, Not set

Southport and Formby District General Hospital, Southport, Not set

Stockport NHS Foundation Trust, Stockport, Not set

North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, Not set

Sherwood Forest Hospitals NHS Foundation Trust, Sutton In Ashfield, Not set

Somerset Foundation Trust, Taunton, Not set

Whiston Hospital, Whiston, Not set

Somerset Foundation Trust, Yeovil, Not set

Conditions: COPD, COPD Exacerbation

Register for Updates

Learn More ›

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants with Pi*ZZ AATD

NCT06405633

Recruiting

The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

02/06/2025

Locations: St. Vincent's Hospital, Melbourne, Fitzroy, Victoria +5 locations

Conditions: Alpha-1 Antitrypsin Deficiency

Register for Updates

Learn More ›

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665

Recruiting

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/05/2025

Locations: CHI St. Vincent, Arkansas, Little Rock, Arkansas +95 locations

CHI St. Vincent, Arkansas, Little Rock, Arkansas

University of Southern California, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

Stanford University, Stanford, California

Medical Center of Aurora, Aurora, Colorado

Western Connecticut Hospital Systems, Danbury, Connecticut

Yale Medicine, New Haven, Connecticut

MedStar Washington Hospital Center, Washington, District of Columbia

Emory University, Atlanta, Georgia

Piedmont Healthcare Inc., Atlanta, Georgia

Lutheran Medical Center, Fort Wayne, Indiana

Indiana University, Indianapolis, Indiana

Ascension St. Vincent, Indianapolis, Indiana

Ochsner Clinic, New Orleans, Louisiana

Maine Medical Center, Portland, Maine

University of Maryland, Baltimore, Maryland

Johns Hopkins, Baltimore, Maryland

Suburban Hospital, Bethesda, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Brigham and Women's Hospital, Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

Baystate Health, Springfield, Massachusetts

University of Michigan, Ann Arbor, Michigan

Mayo Clinic, Rochester, Minnesota

Mid America Health Institute, Kansas City, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Jersey Shore University Medical Center, Neptune, New Jersey

Montefiore Medical Center, Bronx, New York

Northwell Health System, Great Neck, New York

The Mount Sinai Hospital, New York, New York

Columbia University Medical Center, New York, New York

Duke University, Durham, North Carolina

East Carolina University, Greenville, North Carolina

WakeMed, Raleigh, North Carolina

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University Medical Center, Columbus, Ohio

Ascension St. John, Tulsa, Oklahoma

University of Pittsburgh Medical Center, Hermitage, Pennsylvania

University of Pennsylvania, Philadelphia, Pennsylvania

Allegheny Health Network, Pittsburgh, Pennsylvania

Baylor College of Medicine, Houston, Texas

Baylor Research Institute, Plano, Texas

Intermountain CV Research, Murray, Utah

University of Utah, Salt Lake City, Utah

University of Vermont, Burlington, Vermont

University of Virginia Health System, Charlottesville, Virginia

Inova Health, Falls Church, Virginia

West Virginia University, Morgantown, West Virginia

University of Wisconsin, Madison, Wisconsin

University of Alberta Hospital, Edmonton, Alberta

London Health Sciences Centre, London, Ontario

Sunnybrook Hospital, Toronto, Ontario

Montreal Heart Institute, Montreal, Quebec

Centre Hospitalier de l'Université de Montréal, Montreal, Quebec

Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec

University of Ottawa Heart Institute, Ottawa, Not set

Hôpital Laval, Quebec, Not set

Toronto General Hospital, Toronto, Not set

University Heart Center Hamburg, Berlin, Brandenburg

Heart Center Leipzig, Berlin, Brandenburg

University Medical Center Göttingen, Göttingen, Lower Saxony

University Medical Center Jena, Jena, Thuringia

Clinic Bad Neustadt - Medical Center for Heart and Vascular Diseases, Bad Neustadt An Der Saale, Not set

HDZ-NRW Bad Oeynhausen, Bad Oeynhausen, Not set

Charité Berlin - Benjamin Franklin Campus, Berlin, Not set

Charité Berlin - Rudolf Virchow Campus, Berlin, Not set

German Heart Center Berlin, Berlin, Not set

University Hospital Bonn, Bonn, Not set

Medical Center Braunschweig, Braunschweig, Not set

Heinrich Heine University Düsseldorf, Düsseldorf, Not set

Frankfurt University Hospital, Frankfurt, Not set

University Medical Center Frankfurt, Frankfurt, Not set

Heart Center, University of Freiburg, Freiburg, Not set

University Medical Center Heidelberg, Heidelberg, Not set

University Medical Center Schleswig-Holstein Kiel, Kiel, Not set

University Medical Center Schleswig-Holstein Lübeck, Lübeck, Not set

University Hospital Magdeburg, Magdeburg, Not set

German Heart Center Munich, Munich, Not set

Medical Center of the Ludwig-Maximilians-University Munich, Munich, Not set

Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, England

Barts Health NHS Trust, London, England

Imperial College Healthcare NHS Trust, London, England

Royal Wolverhampton NHS Trust, Wolverhampton, England

Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, Not set

University Hospitals Bristol NHS Foundation Trust, Bristol, Not set

Royal Papworth Hospital NHS Foundation Trust, Cambridge, Not set

Hull University Teaching Hospitals NHS Trust, Cottingham, Not set

University Hospitals of Leicester NHS Trust, Leicester, Not set

South Tees Hospitals NHS Foundation Trust, Middlesbrough, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Oxford University Hospitals NHS Foundation Trust, Oxford, Not set

University Hospitals Plymouth NHS Trust, Plymouth, Not set

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, Not set

University Hospital Southampton NHS Foundation Trust, Southampton, Not set

University Hospitals Sussex NHS Foundation Trust, Worthing, Not set

Conditions: Atrial Fibrillation, Stroke, Bleeding

Register for Updates

Learn More ›

Fluid Administration and Fluid Accumulation in the Intensive Care Unit

NCT06258616

Recruiting

The goal of this international inception cohort study is to describe fluid administration during admittance to the intensive care unit (ICU), and provide contemporary epidemiological data on fluid accumulation, risk factors, management and outcome in critically ill adult patients.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/05/2025

Locations: Department of Intensive Care, Sygehus Sønderjylland Aabenraa, Aabenraa, Not set +20 locations

Department of Intensive Care, Sygehus Sønderjylland Aabenraa, Aabenraa, Not set

Departmen of Intensive Care, Aalborg, Not set

Department of Intensive Care, University hospital Aarhus, Aarhus, Not set

Department of Intensive Care, Rigshospitalet 4131, Copenhagen, Not set

Department of Intensive Care, Bispebjerg, Copenhagen, Not set

Department of Intensive Care, Herlev Hospital, Herlev, Not set

Department of Intensive Care, Regionshospital Gødstrup, Herning, Not set

Deparment of Intensive care, Nordsjællands hospital, Hillerød, Not set

Department of Intensive Care, Zealand University hospital, Køge, Not set

Department of Intensive Care, Regionshospitalet Randers, Randers, Not set

Department of Intensive Care, University Hospital Zealand, Roskilde, Roskilde, Not set

Department of Intensive Care, Tampere University Hospital, Tampere, Not set

Department of Intensive Care, Landspitali National University Hospital of Iceland, Reykjavík, Not set

Department of Anaesthesiology, Critical Care and Pain Tata Memorial Hospital, Mumbai., Mumbai, Not set

Department of Anaesthesia and Critical Care Vilnuis University Hospital Santariskiu Cinics, Vilnuis, Vilnius, Not set

Department of Intensive Care Wellington Hospital (CCDHB), Newton, Wellington, Wellington, Not set

Department of Intensive Care, Stavanger University Hospital, Stavanger, Not set

Hospital Clinic of Barcelona, Barcelona, Not set

Helsingborg Hospital, Helsingborg, Not set

Department of Intensive Care, Inselspital, Bern, Not set

General Adult Intensive Care Unit, Critical Care Directorate University Hospital of Wales, Cardiff, Cardiff, Not set

Conditions: Fluid Overload, Fluid Therapy, Fluid Accumulation

Register for Updates

Learn More ›

Capillary OGTT Study

NCT06815081

Recruiting

Type 1 diabetes (T1D) is a chronic condition, affecting 1 in 490 children under the age of 15 years. It is caused by the immune system damaging the pancreas, the organ which makes insulin. T1D has recognised stages before symptoms develop, providing an opportunity for early diagnosis, education and treatment which may delay the onset of symptoms. Early diagnosis often relies on a test called the oral glucose tolerance test (OGTT), which is commonly used but not well tolerated, possibly because i... Read More

Type 1 diabetes (T1D) is a chronic condition, affecting 1 in 490 children under the age of 15 years. It is caused by the immune system damaging the pancreas, the organ which makes insulin. T1D has recognised stages before symptoms develop, providing an opportunity for early diagnosis, education and treatment which may delay the onset of symptoms. Early diagnosis often relies on a test called the oral glucose tolerance test (OGTT), which is commonly used but not well tolerated, possibly because it requires a drip inserted into the vein, and several blood samples taken over 2-3 hours in a healthcare setting. This study aims to test whether an OGTT using a finger-prick to test glucose, can be done at home. This is the 'GTT@home'. The finger-prick creates a drop of blood, which is done before and two hours after drinking a sugary drink. Investigators will also explore whether a continuous glucose monitor (CGM), which reads glucose levels through the skin could be an alternative. The investigators plan to recruit 90 children and young people, across two groups to assess the GTT@home. To understand the experiences of those involved in monitoring, the investigators will invite young people, parents and healthcare workers to take part in an interview, to understand the impact of testing to predict clinical T1D. Group 1 will assess the accuracy of measuring glucose from a finger-prick blood test when compared to a blood test from the vein. The investigators will recruit individuals who are having an OGTT as part of a research study, for clinical care, or if individuals have agreed to have an OGTT for this study. Those with T1D will be invited to wear a CGM to explore its use as an additional, practical alternative. Group 2 will assess how well the GTT@home test works when done at home and how acceptable it is. This will only be offered to those known to be at risk of T1D. These studies will help investigators to understand if the GTT@home can be used in routine care. Read Less

Gender:

ALL

Ages:

17 years and below

Trial Updated:

02/04/2025

Locations: Noah's Ark Childrens Hospital for Wales, Cardiff, Not set +3 locations

Conditions: Type 1 Diabetes (T1D)

Register for Updates

Learn More ›

A Phase 1b Trial to Evaluate Safety of MB097 in Combination with Pembrolizumab in Melanoma Patients

NCT06540391

Recruiting

A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/04/2025

Locations: Centre Georges Francois Leclerc, Dijon, Not set +18 locations

Conditions: Melanoma

Register for Updates

Learn More ›

Single-Cell Sequencing Analysis of Radiation Pneumonitis Signals In Patients Treated For Cancer With Radiotherapy

NCT06557343

Recruiting

Patients with signs of radiation induced lung inflammation, who are referred for a clinical bronchoscopy for investigation, will have a sample sent for single cell sequencing. This is a novel technique which allows for identification of which cells are present and what they are doing. This hopes to better understand radiation pneumonitis, a dose-limiting toxicity in cancer treatment which can be highly morbid and even fatal.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/04/2025

Locations: Centre for Information Research, University of Edinburgh, Edinburgh, Not set +2 locations

Conditions: Radiation Pneumonitis

Register for Updates

Learn More ›

Capturing MultiORgan Effects of COVID-19

NCT04510025

Recruiting

The C-MORE study is prospective observational holistic longitudinal study which will characterise the prevalence of multi-organ injury among COVID-19 survivors post hospital discharge and assess its effects on quality of life, exercise tolerance and mental health.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

02/04/2025

Locations: University of Oxford, Oxford, Not set

Conditions: Coronavirus Infection, Multi-Organ Disorder

Register for Updates

Learn More ›

Effectiveness and Safety of Knee Cartilage Lesion Treatment Using CartiONE: 1-to-13 Year Follow-up.

NCT06809231

Recruiting

CartiONE is a technique used in autologous articular-chondrocyte-based treatments for symptomatic focal articular-cartilage lesions of the knee. The CartiONE technique was evaluated in combination with an osteochondrally placed, biodegradable, biocompatible, load-bearing copolymer (PolyActive) scaffold in the INSTRUCT trial (NCT01041885). To evaluate the clinical effectiveness of the CartiONE technique and confirm its safety, in this study retrospective baseline data and follow-up data, document... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/04/2025

Locations: UZ Ghent, Ghent, Oost-Vlaanderen +4 locations

Conditions: Knee Cartilage Lesion

Register for Updates

Learn More ›

All Clinical Trials in United Kingdom

Match to Clinical Trials